Circulating Tumor Cells in Prostate Cancer Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01414712|
Recruitment Status : Terminated
First Posted : August 11, 2011
Last Update Posted : March 5, 2013
|Condition or disease||Intervention/treatment|
|Prostate Cancer||Other: Blood Drawing|
SBRT (stereotactic body radiotherapy) may decrease or actually increase CTC levels in patients with cancer, and knowledge about the effects of different therapies, including SBRT, on CTC levels will be of general interest to the oncology community. Patients will undergo blood draws at defined times as indicated below.
- Prior to CT-simulation, but more than 2 days after digital rectal examination
- Within 24 hours following CT simulation (an endorectal balloon is used at the time of simulation)
- Within 24 hours following the first treatment
- Within 24 hours following the third treatment
- Within 1 week following the fifth treatment
|Study Type :||Observational|
|Actual Enrollment :||2 participants|
|Official Title:||Circulating Tumor Cells in Patients Undergoing Stereotactic Body Radiotherapy for Low- and Intermediate-Risk Prostate Cancer|
|Study Start Date :||July 2011|
|Actual Primary Completion Date :||December 2011|
|Actual Study Completion Date :||December 2011|
|prostate cancer patients||
Other: Blood Drawing
Blood Drawing to measure circulating tumor cells counts.
Other Name: Blood Drawing for prostate cancer patients who undergo stereotactic body radiotherapy
- To review the level of changes in circulating tumor cells with radiation. [ Time Frame: 2 weeks ]The investigator will review the coutns of circulating tumor cells (CTC). If there are significant changes in CTC levels with radiation, future studies will determine the prognostic significance of this information.
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01414712
|United States, Texas|
|University of Texas Southwestern Medical Center|
|Dallas, Texas, United States, 75390|
|Principal Investigator:||Jeffrey Meyer, MD||University of Texas Southwestern Medical Center|